Longevity Executes Merger with 20/20 BioLabs to Enhance Diagnostics Footprint
Deal News | Apr 14, 2025 | EIN
Longevity Health Holdings, a company focused on human longevity through innovative bio-aesthetic and diagnostic products, has announced a merger with 20/20 BioLabs, a leader in laboratory tests for chronic disease detection. The merger, an all-stock transaction set to maintain Longevity’s Nasdaq symbol XAGE, aims to enhance Longevity’s foothold in diagnostics to complement its bio-aesthetic offerings and expand into nutrition. The unified entity will focus on addressing chronic disease under the 'Healthy Aging, Inside and Out' initiative. Post-merger, the new board will consist of six directors, split between both parties, with Rajiv Shukla as Chairman and Jonathan Cohen as CEO. The merger is aligned with Longevity's strategic rebranding and is anticipated to double its fiscal 2025 revenue. Expected to close in Q3 2025, the merger aligns with Longevity's mission to drive synergies across bio-aesthetic and diagnostic offerings. Potential further acquisitions are slated for FY 2025, paving the path to profitability.
Sectors
- Healthcare and Diagnostics
- Biotechnology
Geography
- United States – Both companies are operational within the United States, with 20/20 BioLabs running a lab in Gaithersburg, MD, and the article addressing health concerns relevant to American stakeholders.
Industry
- Healthcare and Diagnostics – The article involves Longevity Health Holdings and 20/20 BioLabs, both of which operate within the healthcare sector, particularly focusing on diagnostics and bio-aesthetics.
- Biotechnology – Longevity Health Holdings focuses on regenerative bio-aesthetics and the article highlights their efforts in technological innovation and clinical applications in healthy aging.
Financials
- $99 million – Post-Closing equity valuation of the combined company.
- $50 million – Pre-money equity valuation of 20/20 BioLabs.
- $3-4 million to $7-8 million – Expected revenue growth post-merger doubling Longevity’s fiscal year 2025 anticipated revenue.
- Over $1 million – Expected operational savings and synergies in fiscal year 2025 following the merger.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Longevity Health Holdings, Inc. | Bidding Company | Company | A company focused on longevity and healthy aging through innovative bio-aesthetic, diagnostic, and nutritional products. |
| 20/20 BioLabs, Inc. | Target Company | Company | A laboratory test provider focusing on early detection and proactive management of chronic disease risk. |
| Jonathan Cohen | CEO of Merged Company | Person | Current CEO of 20/20 BioLabs, who will be appointed CEO of the combined company post-merger. |
| Rajiv Shukla | Chairman of Merged Company | Person | Chairman and CEO of Longevity Health Holdings set to remain as Chairman post-merger. |